Table 1 COVID-19 studies reported in ImmPort as of April 18, 2021
ImmPort Study ID | Title | PMID | Comments | Citation |
|---|---|---|---|---|
SDY1667 | Cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans | 32753554 | Shared epitopes with common cold coronaviruses | [20] |
SDY1640 | T and B cell responses to SARS-CoV-2 coronavirus | 32473127 | Cytokine signatures/markers | [26] |
SDY1662 | An inflammatory cytokine signature predicts Covid-19 severity and survival | 32839624 | Inflammatory cytokine signatures | [30] |
SDY1665 | Longitudinal analyses reveal immunological misfiring in severe COVID-19 (Companion study to SDY1648) | 32717743 | Cytokine signatures | [31] |
SDY1648 | Sex differences in immune responses to SARS-CoV-2 (Companion study to SDY1655) | 32846427 | Overlapped genes with significant differences in female and male patients | [12] |
SDY1641 | Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension | 32228222 | RAS inhibitor drugs effective against hypertension | [49] |